We are live on ! Find out more
SCPH

scPharmaceuticals
SCPH

Delisted

SCPH was delisted on the 6th of October, 2025.

Back to rankings

26 hedge funds and large institutions have $44.5M invested in scPharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more capital invested

Capital invested by funds: $23.5M → $44.5M (+$21M)

1.11% more ownership

Funds ownership: 39.67% → 40.78% (+1.1%)

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

16% less funds holding

Funds holding: 31 → 26 (-5)

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

Holders
26
Holders Change
-5
Holders Change %
-16.13%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$943K
2
Renaissance Technologies
Renaissance Technologies
New York
+$376K
3
JP Morgan Chase
JP Morgan Chase
New York
+$268K
4
EP
Eversept Partners
New York
+$267K
5
Morgan Stanley
Morgan Stanley
New York
+$205K

Top Sellers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
-$317K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$126K
3
Millennium Management
Millennium Management
New York
-$108K
4
PP
Paloma Partners
Connecticut
-$96K
5
SG Americas Securities
SG Americas Securities
New York
-$41K

SCPH Hedge Fund Activity: Q3 2019 in Review

26 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q3 2019, worth a combined $44.5M — up 89% from $23.5M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of SCPH and 5 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $943K. The largest seller was Northern Trust, cutting an estimated $317K.

  • 26 institutional investors held scPharmaceuticals (SCPH) as of Q3 2019, down from 31 in Q2 2019.
  • Funds reported $44.5M of scPharmaceuticals stock for Q3 2019, up 89% quarter-over-quarter.
  • 5 funds opened new scPharmaceuticals positions in Q3 2019 and 10 closed out, a net change of -5 holders.
  • The largest scPharmaceuticals buyer in Q3 2019 was Vanguard Group, an estimated $943K added.
  • The largest scPharmaceuticals seller in Q3 2019 was Northern Trust, an estimated $317K sold.

Based on aggregated 13F filings for Q3 2019.